You are in: eMedicine Specialties >
Obstetrics and Gynecology > Medical Problems in Pregnancy
Hypertension and Pregnancy
Article Last Updated: Dec 13, 2007
AUTHOR AND EDITOR INFORMATION
Section 1 of 11
Author: Paul Gibson, MD, Assistant Professor, Departments of Medicine and Obstetrics and Gynecology, Division of General Internal Medicine, University of Calgary
Paul Gibson is a member of the following medical societies: Alberta Medical Association, Canadian Society of Internal Medicine, Royal College of Physicians and Surgeons of Canada, and Society of Obstetric Medicine
Coauthor(s):
Michael P Carson, MD, Associate Professor, Departments of Medicine and Obstetrics and Gynecology, Drexel University College of Medicine; Chief, Division of Internal Medicine, Director, Obstetric Medicine Service, St Peter's University Hospital
Editors: Gerard S Letterie, DO, Associate Clinical Professor, Medical Director of In-vitro Fertilization Lab, Department of Obstetrics and Gynecology, Virginia Mason Medical Center, University of Washington; Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine; Frederick B Gaupp, MD, Consulting Staff, Department of Family Practice, Assumption Community Hospital; Carl V Smith, MD, The Distinguished Chris J and Marie A Olson Chair of Obstetrics and Gynecology, Professor, Department of Obstetrics and Gynecology, University of Nebraska Medical Center
Author and Editor Disclosure
Synonyms and related keywords:
hypertension and pregnancy, pregnancy-induced hypertension, PIH, preeclampsia, hyperpiesis, hyperpiesia, high blood pressure, gestational hypertension, chronic hypertension, preeclampsia-eclampsia, preeclampsia superimposed on chronic hypertension, gestational hypertension, transient hypertension of pregnancy, chronic hypertension in the latter half of pregnancy
Background
Hypertension is the most common medical problem encountered during pregnancy, complicating 2-3% of pregnancies. Hypertensive disorders during pregnancy are classified into 4 categories, as recommended by the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy: 1) chronic hypertension, 2) preeclampsia-eclampsia, 3) preeclampsia superimposed on chronic hypertension, and 4) gestational hypertension (transient hypertension of pregnancy or chronic hypertension identified in the latter half of pregnancy). This terminology is preferred over the older but widely used term PIH (pregnancy-induced hypertension) because it is more precise.
Chronic hypertension is defined as blood pressure exceeding 140/90 mm Hg before pregnancy or before 20 weeks' gestation. When hypertension is first identified during a woman's pregnancy and she is at less than 20 weeks' gestation, blood pressure elevations usually represent chronic hypertension. In contrast, new onset of elevated blood pressure readings after 20 weeks' gestation mandates the consideration and exclusion of preeclampsia. Preeclampsia occurs in approximately 5% of all pregnancies, 10% of first pregnancies, and 20-25% of women with a history of chronic hypertension. Hypertensive disorders in pregnancy may cause maternal and fetal morbidity and remain a leading source of maternal mortality.
Pathophysiology
Chronic hypertension Chronic hypertension is a primary disorder in 90-95% of cases. Secondary causes are briefly discussed in Causes. Preeclampsia Although the exact pathophysiologic mechanism is not clearly understood, preeclampsia is primarily a disorder of endothelial function with associated vasospasm. In some cases, pathology demonstrates evidence of placental insufficiency with associated abnormalities such as diffuse placental thrombosis, an inflammatory placental decidual vasculopathy, and/or abnormal trophoblastic invasion of the endometrium. This suggests that abnormal placental development or placental damage from diffuse microthrombosis may be central to the development of this disorder. Evidence also indicates that an altered maternal immune response to fetal/placental tissue may contribute to the development of preeclampsia. The widespread endothelial dysfunction may manifest in a pregnant woman as dysfunction of multiple organ systems, including the central nervous, hepatic, pulmonary, renal, and hematological systems. Endothelial damage leads to pathologic capillary leak that can manifest in the mother as rapid weight gain, nondependent edema (face or hands), pulmonary edema, and/or hemoconcentration. When the placenta is diseased, it can affect the fetus via decreased utero-placental blood flow. This decrease in perfusion can manifest clinically as nonreassuring fetal heart rate testing, low scores on a biophysical profile, oligohydramnios, and as fetal growth restriction in severe cases. Hypertension occurring in preeclampsia is due primarily to vasospasm, with arterial constriction and relatively reduced intravascular volume compared to normal pregnancy. The vasculature of normal pregnant women typically demonstrates decreased responsiveness to vasoactive peptides such as angiotensin-II and epinephrine. Women who develop preeclampsia show a hyperresponsiveness to these hormones, an alteration that may be seen even before the hypertension becomes apparent. In addition, their blood pressures are labile and the normal circadian blood pressure rhythms may be blunted or reversed. Transient hypertension Transient hypertension refers to hypertension occurring in late pregnancy without any other features of preeclampsia, with normalization of the blood pressure postpartum. The pathophysiology of transient hypertension is unknown, but it may be a harbinger of chronic hypertension later in life.
Frequency
United States
Chronic hypertension occurs in up to 22% of women of childbearing age, with the prevalence varying according to age, race, and body mass index. Using population-based data, approximately 1% of pregnancies are complicated by chronic hypertension, 5-6% by gestational hypertension (without proteinuria), and 1-2% by preeclampsia.
Mortality/Morbidity
- Hypertensive disorders in pregnancy are among the leading causes of maternal mortality, along with thromboembolism, hemorrhage and nonobstetric injuries. Between 1991 and 1999, pregnancy-induced hypertension caused 15.7% of maternal deaths in the United States.
- While maternal diastolic blood pressure (DBP) greater than 110 mm Hg is associated with an increased risk for placental abruption and fetal growth restriction, superimposed preeclamptic disorders cause most of the morbidity due to chronic hypertension during pregnancy. Severe maternal complications include eclamptic seizures, intracerebral hemorrhage, pulmonary edema due to capillary leak or myocardial dysfunction, acute renal failure due to vasospasm, proteinuria greater than 4-5 g/d, hepatic swelling with or without liver dysfunction, and disseminated intravascular coagulation and/or consumptive coagulopathy (rare). Consumptive coagulopathy usually is associated with placental abruption and is uncommon as a primary manifestation of preeclampsia.
- Fetal complications include abruptio placentae, intrauterine growth restriction, premature delivery, and intrauterine fetal death.
Race
Black women have higher rates of preeclampsia complicating their pregnancies compared to other racial groups, mainly because they have a greater prevalence of underlying chronic hypertension. Among women aged 30-39 years, chronic hypertension is present in 22.3% of black people, 4.6% of white people, and 6.2% of Mexican Americans. Hispanic women generally have blood pressure levels that are the same as or lower than those of non-Hispanic white women.
Age
Preeclampsia is more common at the extremes of maternal age (<18 y or >35 y). The increased prevalence of chronic hypertension and other comorbid medical illnesses in women older than 35 years may explain the increased frequency of preeclampsia among older gravidas.
History
Determining whether elevated blood pressure identified during pregnancy is due to chronic hypertension or to preeclampsia is a challenge. Clinical characteristics obtained via history, physical examination, and certain laboratory investigations may be used to help clarify the diagnosis.
- Gestational age
- Hypertension prior to 20 weeks' gestation is almost always due to chronic hypertension; preeclampsia is rare prior to the third trimester.
- New-onset or worsening hypertension after 20 weeks' gestation should lead to a careful evaluation for manifestations of preeclampsia.
- The diagnosis of severe hypertension or preeclampsia in the first or early second trimester necessitates exclusion of gestational trophoblastic disease and/or molar pregnancy.
- Women diagnosed with severe or early preeclampsia (in the second trimester or early third trimester) have a higher prevalence of thrombophilias. Studies are ongoing to evaluate whether administering anticoagulants in subsequent pregnancies decreases the risk of recurrent preeclampsia.
- Maternal personal risk factors for preeclampsia
- First pregnancy
- New partner/paternity
- Age younger than 18 years or older than 35 years
- History of preeclampsia
- Family history of preeclampsia in a first-degree relative
- Black race
- Obesity (BMI ³35)
- Interpregnancy interval less than 2 years or more than 10 years
- Maternal medical risk factors for preeclampsia
- Chronic hypertension, especially secondary causes of chronic hypertension such as hypercortisolism, hyperaldosteronism, pheochromocytoma, or renal artery stenosis
- Preexisting diabetes (type 1 or type 2), especially with microvascular disease
- Renal disease
- Systemic lupus erythematosus
- Obesity
- Thrombophilia
- Placental/fetal risk factors for preeclampsia
- Multiple gestations
- Hydrops fetalis
- Gestational trophoblastic disease
- Triploidy
- Symptoms of preeclampsia
- Visual disturbances typical of preeclampsia are scintillations and scotomata. These disturbances are presumed to be due to cerebral vasospasm.
- Headache is of new onset and may be described as frontal, throbbing, or similar to a migraine headache.
- Epigastric pain is due to hepatic swelling and inflammation, with stretch of the liver capsule. Pain may be of sudden onset, is typically constant, and may be moderate-to-severe in intensity.
- While mild lower extremity edema is common in normal pregnancy, rapidly increasing or nondependent edema may be a signal of developing preeclampsia. Edema is no longer included among the criteria for diagnosis of preeclampsia.
- Rapid weight gain is a result of edema due to capillary leak as well as renal sodium and fluid retention.
Physical
- Physical findings in preeclampsia
- Blood pressure
- Blood pressure should be measured in the sitting position, with the cuff at the level of the heart. Inferior vena caval compression by the gravid uterus while the patient is supine can alter readings substantially, leading to an underestimation of the blood pressure. Blood pressures measured in the left lateral position similarly may yield falsely low values if the blood pressure is measured in the higher arm, unless the cuff is carefully maintained at the level of the heart.
- Women should be allowed to sit quietly for 5-10 minutes before each blood pressure measurement.
- Korotkoff sounds I (the first sound) and V (the disappearance of sound) should be used to denote the systolic blood pressure (SBP) and DBP, respectively. In about 5% of women, an exaggerated gap exists between the fourth (muffling) and fifth (disappearance) Korotkoff sounds, with the fifth sound approaching zero. In this setting, both the fourth and fifth sounds should be recorded (eg, 120/80/40 with sound I = 120, sound IV = 80, sound V = 40) as the fourth sound will more closely approximate the true DBP.
- Maternal SBP greater than 160 mm Hg or DBP greater than 110 mm Hg denotes severe disease; depending on the gestational age and maternal status, delivery should be considered for sustained BPs in this range.
- Many automated blood pressure cuffs provide reasonable estimates of true blood pressure during normal pregnancy (especially those validated for pregnancy) but tend to underestimate blood pressure in preeclamptic women. Only a few automated BP cuffs have been validated in preeclampsia. Manual blood pressure measurement with a mercury sphygmomanometer remains the criterion standard in this setting.
- Home and ambulatory BP measurements are increasingly being used in the pregnant population. Assuming the BP device is accurate (validated relative to an office measurement) they may provide valuable additional data regarding hypertension severity and control during pregnancy.
- Retinal vasospasm is a severe manifestation of maternal disease; consider delivery.
- Retinal edema is known as serous retinal detachment. This can manifest as severely impaired vision if the macula is involved. It generally reflects severe preeclampsia and should lead to prompt consideration of delivery. The condition typically resolves upon completion of pregnancy and resolution of the hypertension and fluid retention.
- Right upper quadrant (RUQ) abdominal tenderness stems from liver swelling and capsular stretch. Consider delivery.
- Brisk, or hyperactive, reflexes are common during pregnancy. Clonus is a sign of neuromuscular irritability that usually reflects severe preeclampsia.
- Approximately 30% of pregnant women will have some lower extremity edema as part of their normal pregnancy. A sudden worsening in dependent edema, edema in nondependent areas (such as the face and hands), or rapid weight gain suggest a pathologic process and warrant further evaluation for preeclampsia.
- Signs suggesting a secondary medical cause of chronic hypertension
- Centripetal obesity, "buffalo hump," and/or wide purple abdominal striae suggest glucocorticoid excess.
- A systolic bruit heard over the abdomen or in the flanks suggests renal artery stenosis.
- Radiofemoral delay or diminished pulses in lower versus upper extremities suggests coarctation of the aorta.
- Clinical signs may demonstrate hyperthyroidism, hypothyroidism, or growth hormone excess.
- Signs of end-organ damage from chronic hypertension
- S4 on cardiac auscultation is not a normal finding in pregnancy. It suggests left ventricular hypertrophy or diastolic dysfunction due to preeclampsia-induced vasospasm.
- Despite a well-conducted phonocardiographic study of pregnant women that found an S3 to be common in normal pregnancy, the authors' findings at busy obstetric centers have not supported this. In the presence of preeclampsia, any cardiac gallop may be a pathological finding and warrants further evaluation.
- Diminished distal pulses due to peripheral vascular disease may be identified.
- Retinal changes of chronic hypertension may be noted.
- Carotid bruits may reflect atherosclerotic disease due to longstanding hypertension.
Causes
- Chronic hypertension
- Chronic hypertension may be either essential (90%) or secondary to some identifiable underlying disorder, such as renal parenchymal disease (eg, polycystic kidneys, glomerular or interstitial disease), renal vascular disease (eg, renal artery stenosis, fibromuscular dysplasia), endocrine disorders (eg, adrenocorticosteroid or mineralocorticoid excess, pheochromocytoma, hyperthyroidism or hypothyroidism, growth hormone excess, hyperparathyroidism), coarctation of the aorta, or oral contraceptive use.
- About 20-25% of women with chronic hypertension develop preeclampsia during pregnancy.
- Preeclampsia
- The exact cause is not known.
- The widespread endothelial dysfunction manifests primarily with maternal effects and has the potential to cause dysfunction of multiple organ systems, including the brain and the hepatic, pulmonary, renal, and hematological systems. The endothelial damage leads to pathologic capillary leak that can manifest in the mother as rapid weight gain, edema of the face or hands, pulmonary edema, and/or hemoconcentration resulting in hemoglobin greater than 12 g/dL or creatinine greater than 0.8 mg/dL. Renal biopsy may show glomerular endotheliosis that is associated with proteinuria greater than 300 mg in 24 hours.
- Effects on the placenta include in situ thrombosis and decidual vasculopathy that can affect the fetus via decreased utero-placental blood flow. This decrease in flow can manifest clinically as nonreassuring fetal heart rate testing, low score on a biophysical profile, oligohydramnios, and fetal growth restriction in severe cases.
Antiphospholipid Antibody Syndrome and Pregnancy
Antithrombin Deficiency
Aortic Coarctation
Autoimmune Thyroid Disease and Pregnancy
Cardiomyopathy, Peripartum
Common Pregnancy Complaints and Questions
Cushing Syndrome
Diabetes Mellitus and Pregnancy
Disseminated Intravascular Coagulation
Eclampsia
Encephalopathy, Hypertensive
Evaluation of Fetal Death
Evaluation of Gestation
Fetal Growth Restriction
Gastrointestinal Disease and Pregnancy
Glomerulonephritis, Acute
Glomerulonephritis, Chronic
Graves Disease
Hashimoto Thyroiditis
Hematologic Disease and Pregnancy
Hemolytic-Uremic Syndrome
Hydatidiform Mole
Hyperaldosteronism, Primary
Hyperparathyroidism
Hypertension
Hypertension, Malignant
Hyperthyroidism
Hypothyroidism
Nephrotic Syndrome
Normal Labor and Delivery
Preeclampsia (Toxemia of Pregnancy)
Protein C Deficiency
Protein S Deficiency
Pulmonary Disease and Pregnancy
Systemic Lupus Erythematosus
Systemic Lupus Erythematosus and Pregnancy
Teratology and Drug Use During Pregnancy
Thrombotic Thrombocytopenic Purpura
Other Problems to be Considered
Assessment of fetal well-being
Lab Studies
- Laboratory testing to evaluate chronic hypertension includes testing for target organ damage, potential secondary causes of hypertension, and other risk factors.
- Studies include: urinalysis; CBC count; and serum sodium, potassium, creatinine, and glucose levels (the presence of high levels of progesterone, an aldosterone antagonist, during a normal pregnancy may mask the hypokalemia from hyperaldosteronism).
- Optional tests include creatinine clearance, microalbuminuria, 24-hour urinary protein, serum calcium, uric acid, glycosylated hemoglobin, thyroid-stimulating hormone (TSH), and an ECG.
- Serum lipids (ie, total cholesterol, high-density lipoprotein [HDL], low-density lipoprotein [LDL], triglycerides) predictably increase during pregnancy, so defer measurement until the postpartum period.
- The increase in endogenous corticosteroid levels during normal pregnancy makes it difficult to diagnose secondary hypertension due to adrenal hormone excess.
- Routine tests when evaluating a patient for preeclampsia include: CBC count, electrolytes, BUN, creatinine, liver enzymes and bilirubin, and a urine dip for protein.
- CBC
- In cases in which an incidental platelet count is less than 150,000/µL, 75% are secondary to dilutional thrombocytopenia of pregnancy, 24% are due to preeclampsia, and about 1% of cases are due to other platelet disorders not related to pregnancy. Counts less than 100,000/µL suggest preeclampsia or ITP.
- Hemoglobin levels greater than 13 g/dL suggest the presence of hemoconcentration. Low levels may be due to microangiopathic hemolysis or iron deficiency.
- Urinalysis may be used as a screen for proteinuria. Trace levels to +1 proteinuria are acceptable, but levels of +2 or greater are abnormal and should be quantified with a 24-hour urine collection or spot urine protein:creatinine ratio.
- Recently, spot urine specimens for protein:Cr ratios have been validated as screening tools for abnormal proteinuria during pregnancy. They appear to be more accurate than urinalysis, although an abnormal result should still be confirmed with a 24-hour urine collection.
- Serum creatinine usually is less than 0.8 mg/dL during pregnancy; higher levels suggest intravascular volume contraction or renal involvement in preeclampsia.
- A serum uric acid level greater than 5 mg/dL is abnormal and is a sensitive, but nonspecific, marker of tubular dysfunction in preeclampsia.
- Elevated levels of hepatic transaminases may reflect hepatic involvement in preeclampsia and may occur in the absence of epigastric/RUQ pain.
- In a 24-hour urine collection, the reference range for protein excretion in pregnancy is up to 300 mg/d. Higher levels are abnormal and may reflect renal involvement in preeclampsia. Creatinine clearance increases approximately 50% during pregnancy, and levels less than 100 mL/min suggest renal dysfunction that is either chronic or due to preeclampsia.
- Examination of the peripheral blood smear for evidence of microangiopathic hemolysis and thrombocytopenia may reveal the presence of red blood cell (RBC) fragments. In this setting, the diagnoses of hemolytic-uremic syndrome (HUS), thrombotic thrombocytopenic purpura (TTP), and HELLP syndrome (hemolysis, elevated liver enzymes, and low platelet [count]) should also be considered.
- Prothrombin time (PT) and/or international normalized ratio (INR) and/or activated partial prothrombin time (aPTT) results may be abnormal in consumptive coagulopathy and disseminated intravascular coagulopathy complicating severe preeclampsia. Checking the PT/INR/aPTT is not necessary in the absence of abnormal liver transaminases or thrombocytopenia.
- Abnormal values of lactate dehydrogenase (LDH), bilirubin, haptoglobin, fibrinogen, and D-dimers may confirm the presence of hemolysis and disseminated intravascular coagulopathy, along with coagulation testing. Checking LDH, bilirubin, haptoglobin, fibrinogen, and D-dimers is unnecessary unless PT/INR/aPTT results are abnormal, thrombocytopenia is present, or the hemoglobin level is dropping.
Imaging Studies
- Imaging studies should not be performed in an unstable patient and should not delay rapid facilitated delivery in a woman thought to have severe preeclampsia or eclampsia.
- New seizures in pregnancy suggest preeclampsia-eclampsia, but primary neurological disorders must be excluded. Blood tests to order when evaluating eclampsia include those suggested to evaluate for preeclampsia.
- Chest radiograph
- Obtain chest radiographs to evaluate for pulmonary edema in the setting of dyspnea or hypoxia occurring in a woman with preeclampsia.
- The fetal ionizing radiation exposure of one maternal chest radiograph with abdominal shielding is only 0.001 rads. While no dose of ionizing radiation is absolutely safe during pregnancy, a commonly held acceptable cumulative dose is 5 rads during pregnancy (approximately 5000 maternal chest radiographs could be performed before reaching this safety threshold).
- CT scan of the brain
- Perform a CT scan to exclude cerebral hemorrhage in the setting of seizures, severe headache, or altered level of consciousness. The fetal radiation exposure with abdominal shielding is well under the permissible 5 rads. CT scan can also be used to exclude mass lesion.
- Findings in women with preeclampsia may include bilateral hypodense areas, called venous infarcts or posterior reversible leukoencephalopathy, in the occipital and parietal regions. They represent focal and reversible areas of edema that are the result of capillary leak or focal areas of impaired venous flow. Generally, these areas resolve as the preeclamptic process reverses.
- MRI of the brain
- An MRI may be performed to evaluate for abnormalities of the cerebral cortex (ie, edema, infarction, hemorrhage) in preeclamptic women with severe visual disturbance, seizures, or altered mental status. An MRI is more sensitive than a CT scan for detecting cerebral cortical abnormalities but less useful in detecting cerebral hemorrhage.
- The classic finding of preeclampsia on T2-weighted images is bilateral occipital bright spots that represent focal edema. This is also known as posterior reversible leukoencephalopathy syndrome. This finding is similar to the changes observed when a nonpregnant patient has hypertensive encephalopathy.
- Magnetic resonance venography also may be performed to exclude cerebral venous sinus thrombosis.
- Ultrasonography or CT scan of the liver may be used to evaluate for subcapsular hemorrhage or infarction in the setting of persistent severe RUQ pain or markedly elevated hepatic transaminases.
- Limited echocardiography may be performed to evaluate for left ventricle hypertrophy (LVH) in chronic hypertension and to exclude cardiomyopathy or occult valvular disease in pregnant women with pulmonary edema.
Other Tests
- Perform 12-lead ECG to evaluate for LVH in women with chronic hypertension.
- Electroencephalogram
- An EEG may be indicated to evaluate recurrent seizure activity, persistent altered level of consciousness, or altered mental status.
- Following eclampsia, the EEG may reveal epileptiform activity. More commonly, the test shows nonspecific diffuse slowing that may persist for several weeks after delivery.
- Fetal monitoring
- Close fetal monitoring under the direction of an obstetrician is essential in pregnant women with preeclampsia. Preeclampsia is a disease of the placenta. When the placenta is severely affected, subtle hypoperfusion of the fetus can occur, which may initially manifest as a decrease in the amniotic fluid level (oligohydramnios), fetal growth restriction, and intrauterine fetal death as a consequence of placental insufficiency. Fetal concerns may be an indication for delivery in women with otherwise mild preeclampsia. In this setting, order fetal assessments twice each week. Obstetricians generally alternate a biophysical profile with a fetal nonstress test to assess fetal well-being. At this point, the authors advise collaboration with a perinatologist.
- Fetal heart rate tracing is a useful tool to assess utero-placental perfusion.
- In women with chronic hypertension, consider advising the obstetrician to obtain a fetal ultrasound at 18 weeks' gestation to document growth. Serial ultrasounds may be necessary to document fetal growth velocity and/or to monitor amniotic fluid volume.
Histologic Findings
Endothelial dysfunction and vasospasm observed in preeclampsia affect multiple regions of the body, including the maternal brain, kidneys, liver, lungs, heart, and placenta. Pathology demonstrates areas of edema, microinfarctions, and microhemorrhage in the affected organs. The placenta typically shows incomplete decidualization of the spiral arterioles, which may be part of the pathogenesis of preeclampsia. The kidneys may reveal glomerular endotheliosis or, more rarely, acute tubular necrosis (ATN) or cortical necrosis.
Medical Care
Although the primary risk of chronic hypertension in pregnancy is development of superimposed preeclampsia, no evidence suggests that pharmacological treatment of mild hypertension reduces the incidence of preeclampsia in this population.
- In normal pregnancy, women's mean arterial pressure drops 10-15 mm Hg over the first half of pregnancy. Most women with mild chronic hypertension (ie, SBP 140-160 mm Hg, DBP 90-100 mm Hg) have a similar decrease in blood pressures and may not require any medication during this period. Conversely, DBP greater than 110 mm Hg has been associated with an increased risk of placental abruption and intrauterine growth restriction, and SBP greater than 160 mm Hg increases the risk of maternal intracerebral hemorrhage. Therefore, pregnant patients should be started on antihypertensive therapy if the SBP is greater than 160 mm Hg or the DBP is greater than 100-105 mmHg. The goal of pharmacologic treatment should be a DBP of less than 100-105 mm Hg and an SBP less than 160 mm Hg.
- Three treatment options are available in cases of mild chronic hypertension in pregnancy.
- Antihypertensive medication may be withheld or discontinued, with subsequent close observation of blood pressure. Because blood pressure drops during normal pregnancy and no data support the use of medication in patients with pressures less than 160/100 mm Hg, the authors recommend this option most often.
- If a woman is on pharmacologic treatment with an agent not recommended for use in pregnancy, she may be switched to an alternative antihypertensive agent preferred for use in pregnancy.
- If a woman is on pharmacologic treatment with an agent acceptable for use in pregnancy, she may continue her current antihypertensive therapy.
- For a woman with chronic hypertension in her first trimester, obtain the following laboratory studies (to serve as baseline values, to be referred to later in the pregnancy if a concern regarding superimposed preeclampsia arises):
- CBC, electrolytes, BUN, creatinine
- Liver enzymes
- Urine dip for protein and a 24-hour urine collection for creatinine clearance and protein excretion
- Women with chronic hypertension in pregnancy should be monitored for the development of worsening hypertension and/or the development of superimposed preeclampsia (risk is approximately 25%). Lab investigations for preeclampsia should be repeated if the patient's blood pressure increases or if she develops signs or symptoms of preeclampsia.
- Women with suspected or diagnosed preeclampsia should be hospitalized for close observation.
- When diagnosed with preeclampsia, delivering the baby always is in the mother's best interest. Any delay in delivery should be due to uncertainty about the diagnosis or immaturity of the fetus.
- When preeclampsia develops remote from term (ie, <34-36 weeks' gestation), attempts often are made to prolong the pregnancy to allow for further fetal growth and maturation. In this setting, both maternal and fetal status must be very closely monitored in a high-risk obstetric centre. Fetal testing should be performed at least twice weekly, using a combination of biophysical profiles and nonstress testing supervised by an obstetrician. Facilitated delivery should occur if either maternal or fetal deterioration is noted, with the mode of delivery decided by obstetric indications.
Consultations
- Women with chronic hypertension in pregnancy should be monitored by an obstetrician. Women with moderate or severe hypertension may benefit from referral to an experienced internist (obstetric medicine specialist), hypertension subspecialist, and/or a specialist in maternal-fetal medicine (perinatologist).
- An internal medicine consultation may be useful in the care of women with chronic hypertension due to a secondary cause, women with target organ damage due to chronic hypertension, and women in whom preeclampsia causes significant organ failure.
- Diagnosis of secondary hypertension during pregnancy can be difficult.
- While not absolutely contraindicated, renal captopril scans involve radioactive isotopes and usually are deferred to the postpartum period.
- Hyperaldosteronism and hypercortisolism are difficult to diagnose during pregnancy due to the high levels of progesterone and the normal increase in endogenous cortisol output.
Diet
Multiple dietary interventions and supplements have been investigated for a role in preventing preeclampsia (see Deterrence/Prevention), but none has shown any consistent beneficial effect.
Activity
- Women with worsening hypertension during pregnancy often are placed on bed rest or restricted activity, although no scientific evidence demonstrates that this is beneficial in prolonging gestation or reducing maternal or fetal morbidity/mortality.
- Women with hypertension and suspected preeclampsia typically are admitted to a hospital for close observation and investigation. Those with established preeclampsia must be observed very closely, either in hospital or in a comprehensive home monitoring program under the care of an obstetrician.
Women with mild chronic hypertension often do not require antihypertensive therapy during most of pregnancy. Pharmacologic treatment of mild hypertension does not reduce the likelihood of developing preeclampsia later in gestation and increases the likelihood of intrauterine growth restriction. If maternal blood pressure exceeds 160/100 mm Hg, however, drug treatment is recommended. If a pregnant woman's blood pressure is sustained greater than 160 mm Hg systolic and/or 110 mm Hg diastolic at any time, lowering the blood pressure quickly with rapid-acting agents is indicated for maternal safety. Anticonvulsant therapy may be undertaken in the setting of severe preeclampsia (primary prophylaxis) or in the setting of eclamptic seizures (secondary prophylaxis). The most effective agent is IV magnesium sulfate; phenytoin is an alternative, although less effective, therapy. A healthy fetus depends on a healthy mother, so medications should be used when clear benefit to the mother exists. The US Food and Drug Administration (FDA) categorization for drug use during pregnancy is simplistic and sometimes misleading. To quote the FDA descriptions, any medication in class A through D may be used "when the potential benefit justifies the potential risk." An antihypertensive medication class to avoid during pregnancy is angiotensin-converting enzyme (ACE) inhibitors, as they are associated with fetal renal dysgenesis or death when used in the second and third trimesters. Angiotensin II receptor antagonists/blockers are not used during pregnancy because of similar mechanism of action as ACE inhibitors. Diuretics do not cause fetal malformations but are generally avoided in pregnancy as they prevent the physiologic volume expansion seen in normal pregnancy. They may be used in states of volume-dependant hypertension, such as renal or cardiac disease.
Drug Category: Alpha-adrenergic inhibitors
Used to treat chronic hypertension during pregnancy. At low doses, an alpha-adrenergic receptor blocker may be used as monotherapy in the treatment of hypertension. At higher doses, it may cause sodium and fluid to accumulate. As a result, concurrent diuretic therapy may be required to maintain the hypotensive effects of the alpha-receptor blockers.
| Drug Name | Methyldopa (Aldomet) |
| Description | Centrally acting antihypertensive agent widely considered the first-line agent for treatment of hypertension during pregnancy. Studies have revealed no adverse effects on cognitive development up to the age of 7.5 y among children with in utero exposure to methyldopa. |
| Adult Dose | 250 mg PO bid/tid; increase q2d prn; not to exceed 3 g/d |
| Pediatric Dose | 10 mg/kg/d PO divided bid/qid; increase q2d prn to maximum 65 mg/kg/d; not to exceed 3 g/d |
| Contraindications | Documented hypersensitivity; acute liver disease |
| Interactions | Effects may decrease with concurrent administration of barbiturates and TCAs; increase in blood pressure may occur with coadministration of iron supplements, MAOIs, sympathomimetics, phenothiazines, and beta-blockers |
| Pregnancy | B - Usually safe but benefits must outweigh the risks.
|
| Precautions | Adverse effects include somnolence and dry mouth; 15% of women do not tolerate doses necessary to control blood pressure; caution in liver disease; hemolytic anemia and liver disease may occur; reduce dose in renal disease |
Drug Category: Beta-adrenergic receptor blockers
Compete with beta-adrenergic agonists for available beta-receptor sites.
| Drug Name | Labetalol (Normodyne, Trandate) |
| Description | Reasonable first-line medication. Combined alpha- and beta-adrenergic blocking agent widely used in treating hypertension during pregnancy. Not associated with mild fetal growth restriction (unlike some other beta-blockers). Intravenous and oral forms are used as an alternative to hydralazine in severe preeclampsia/eclampsia. |
| Adult Dose | 100 mg IV bid; not to exceed 2400 mg/d BP >170/110 mm Hg: 20 mg IV bolus; subsequent doses of 40 mg followed by 80 mg IV may be administered at 10- to 20-min intervals to achieve BP control; may also be administered as continuous infusion 1 mg/kg/h |
| Pediatric Dose | Not established |
| Contraindications | Documented hypersensitivity; cardiogenic shock, pulmonary edema, bradycardia, atrioventricular block, uncompensated congestive heart failure; reactive airway disease |
| Interactions | Decreases effect of diuretics; increases toxicity of methotrexate, lithium, and salicylates; may diminish reflex tachycardia resulting from nitroglycerin use without interfering with hypotensive effects; cimetidine may increase labetalol blood levels; glutethimide may decrease labetalol effects by inducing microsomal enzymes |
| Pregnancy | C - Safety for use during pregnancy has not been established.
|
| Precautions | Caution in impaired hepatic function; discontinue therapy at signs of liver dysfunction; in elderly patients, a lower response rate and higher incidence of toxicity may be observed |
| Drug Name | Pindolol (Visken) |
| Description | Nonselective beta-blocker with intrinsic sympathomimetic activity (ISA). |
| Adult Dose | 5-15 mg PO bid |
| Pediatric Dose | Not established |
| Contraindications | Documented hypersensitivity; uncompensated congestive heart failure, bradycardia, cardiogenic shock, AV conduction abnormalities; asthma |
| Interactions | Aluminum salts, barbiturates, NSAIDs, penicillins, calcium salts, cholestyramine, and rifampin may decrease bioavailability and plasma levels, possibly resulting in decreased pharmacologic effects; toxicity may increase with coadministration of sparfloxacin, phenothiazines, astemizole [recalled from US market], calcium channel blockers, quinidine, flecainide, and contraceptives; may increase toxicity of digoxin, flecainide, clonidine, epinephrine, nifedipine, prazosin, verapamil, and lidocaine |
| Pregnancy | B - Usually safe but benefits must outweigh the risks.
|
| Precautions | Concern exists that beta-blockers prescribed during pregnancy, particularly atenolol, may be associated with intrauterine growth restriction (pindolol and oxprenolol are preferred agents because their intrinsic ISA may mitigate this risk); none have been associated with any consistent adverse effects, although long-term follow-up studies are lacking |
| Drug Name | Oxprenolol (Apsolox, Trasicor, Captol) |
| Description | Not commercially available in the United States. Nonselective beta-blocker with ISA. |
| Adult Dose | 20-80 mg PO bid/tid |
| Pediatric Dose | Not established |
| Contraindications | Documented hypersensitivity |
| Interactions | Indomethacin reduces antihypertensive effect of oxprenolol; oxprenolol may increase the effects of ergotamine |
| Pregnancy | C - Safety for use during pregnancy has not been established.
|
| Precautions | Concern exists that beta-blockers prescribed during pregnancy, particularly atenolol, may be associated with intrauterine growth restriction (pindolol and oxprenolol are preferred agents because their intrinsic ISA may mitigate this risk); none have been associated with any consistent adverse effects, although long-term follow-up studies are lacking |
| Drug Name | Metoprolol (Lopressor, Toprol XL) |
| Description | Second-line agent because of its similarity to atenolol (see below). Selective beta1-adrenergic receptor blocker that decreases automaticity of contractions. |
| Adult Dose | 50-400 mg PO qd |
| Pediatric Dose | Not established |
| Contraindications | Documented hypersensitivity; uncompensated congestive heart failure, bradycardia, cardiogenic shock, AV conduction abnormalities; asthma |
| Interactions | Aluminum salts, barbiturates, NSAIDs, penicillins, calcium salts, cholestyramine, and rifampin may decrease bioavailability and plasma levels of metoprolol, possibly resulting in decreased pharmacologic effects; toxicity of metoprolol may increase with coadministration of sparfloxacin, phenothiazines, astemizole [recalled from US market], calcium channel blockers, quinidine, flecainide, and contraceptives; metoprolol may increase toxicity of digoxin, flecainide, clonidine, epinephrine, nifedipine, prazosin, verapamil, and lidocaine |
| Pregnancy | C - Safety for use during pregnancy has not been established.
|
| Precautions | Beta-adrenergic blockade may reduce signs and symptoms of acute hypoglycemia and may decrease clinical signs of hyperthyroidism; abrupt withdrawal may exacerbate symptoms of hyperthyroidism, including thyroid storm; monitor patient closely and withdraw the drug slowly; during IV administration, carefully monitor blood pressure, heart rate, and ECG |
| Drug Name | Atenolol (Tenormin) |
| Description | Was associated with mild intrauterine growth restriction when used in randomized trials focusing on the treatment of chronic hypertension during pregnancy. Selectively blocks beta1 receptors with little or no effect on beta2 types. |
| Adult Dose | 50-100 mg PO qd |
| Pediatric Dose | Not established |
| Contraindications | Documented hypersensitivity; congestive heart failure, cardiogenic shock, AV conduction abnormalities, heart block (without a pacemaker); pulmonary edema |
| Interactions | Coadministration with aluminum salts, barbiturates, calcium salts, cholestyramine, NSAIDs, penicillins, and rifampin may decrease effects; haloperidol, hydralazine, loop diuretics, and MAOIs may increase toxicity of atenolol |
| Pregnancy | D - Unsafe in pregnancy
|
| Precautions | Concern exists that beta-blockers prescribed during pregnancy, particularly atenolol, may be associated with intrauterine growth restriction; beta-adrenergic blockade may reduce symptoms of acute hypoglycemia and mask signs of hyperthyroidism; abrupt withdrawal may exacerbate symptoms of hyperthyroidism and cause thyroid storm; monitor patient closely and withdraw drug slowly |
Drug Category: Calcium channel blockers
Inhibit calcium ions from entering slow channels, select voltage-sensitive areas, or vascular smooth muscle.
| Drug Name | Nifedipine (Adalat, Procardia) |
| Description | Appears safe in pregnancy. Because it relaxes smooth muscle, it is occasionally used by obstetricians to treat preterm contractions. Dihydropyridine calcium channel blocker. Exerts its antihypertensive effect through relaxation of smooth muscle, which produces vasodilation. |
| Adult Dose | IR cap: 10-30 mg PO tid; not to exceed 120-180 mg/d SR tab: 30-60 mg PO qd; not to exceed 90-120 mg/d BP >170/110 mm Hg: 10 mg PO initial; repeat dose may be administered in 30 min prn |
| Pediatric Dose | 0.25-0.5 mg/kg/dose PO tid/qid prn |
| Contraindications | Documented hypersensitivity |
| Interactions | Caution with coadministration of any agent that can lower BP, including beta-blockers and opioids; H2 blockers (eg, cimetidine) may increase toxicity; avoid concurrent use with magnesium because of risk of profound hypotension (antidote is IV calcium gluconate) |
| Pregnancy | C - Safety for use during pregnancy has not been established.
|
| Precautions | May cause lower extremity edema; allergic hepatitis (rare) |
Drug Category: Centrally acting alpha-adrenergic agonists
Decrease sympathetic outflow, which causes a decrease in vasomotor tone and heart rate.
| Drug Name | Clonidine (Catapres) |
| Description | Usually a third-line agent if other medications cannot be tolerated. Stimulates alpha2-adrenoreceptors in brain stem, activating an inhibitory neuron, which in turn results in reduced sympathetic outflow. These effects result in a decrease in vasomotor tone and heart rate. |
| Adult Dose | Initial: 0.1 mg PO bid Maintenance: 0.2-1.2 mg/d bid/qid PO; not to exceed 2.4 mg/d |
| Pediatric Dose | Not established |
| Contraindications | Documented hypersensitivity |
| Interactions | TCAs inhibit hypotensive effects of clonidine; coadministration with beta-blockers may potentiate bradycardia; tricyclic antidepressants may enhance hypertensive response associated with abrupt clonidine withdrawal; narcotic analgesics enhance hypotensive effects of clonidine |
| Pregnancy | C - Safety for use during pregnancy has not been established.
|
| Precautions | Caution in cerebrovascular disease, coronary insufficiency, sinus node dysfunction, and renal impairment; abrupt discontinuation may lead to rebound hypertension |
Drug Category: Diuretics
May have a transient effect on intravascular volume by causing an initial drop in cardiac output produced by diuresis.
| Drug Name | Hydrochlorothiazide (Esidrix, HydroDIURIL) |
| Description | Not commonly used to treat hypertension during pregnancy. May have a transient effect on intravascular volume. Inhibits reabsorption of sodium in distal tubules, causing increased excretion of sodium and water, as well as potassium and hydrogen ions. |
| Adult Dose | 25-100 mg PO qd; not to exceed 200 mg/kg/d |
| Pediatric Dose | <6 months: 2-3 mg/kg/d PO divided bid >6 months: 2 mg/kg/d PO divided bid |
| Contraindications | Documented hypersensitivity; anuria, renal decompensation |
| Interactions | Thiazides may decrease effects of anticoagulants, antigout agents, and sulfonylureas; thiazides may increase toxicity of allopurinol, anesthetics, antineoplastics, calcium salts, loop diuretics, lithium, diazoxide, digitalis, amphotericin B, and nondepolarizing muscle relaxants |
| Pregnancy | C - Safety for use during pregnancy has not been established.
|
| Precautions | Prevents normal physiologic volume expansion that occurs in pregnancy and may reduce uterine blood flow; restrict use to women with volume-overload states (eg, renal or cardiac disease) |
| Drug Name | Furosemide (Lasix) |
| Description | Not commonly used to treat hypertension during pregnancy. Is often used to treat pulmonary edema associated with preeclampsia. Increases excretion of water by interfering with chloride-binding cotransport system, which in turn inhibits sodium and chloride reabsorption in ascending loop of Henle and distal renal tubule. |
| Adult Dose | 10 mg IV initial dose 20-80 mg/d PO/IV/IM; titrate up to 600 mg/d for severe edematous states |
| Pediatric Dose | 1-2 mg/kg/dose PO; not to exceed 6 mg/kg/dose; not to administer >q6h 1 mg/kg IV/IM slowly under close supervision; not to exceed 6 mg/kg |
| Contraindications | Documented hypersensitivity; hepatic coma; anuria; state of severe electrolyte depletion |
| Interactions | Metformin decreases furosemide concentrations; furosemide interferes with hypoglycemic effect of antidiabetic agents and antagonizes muscle-relaxing effect of tubocurarine; auditory toxicity appears to be increased with coadministration of aminoglycosides and furosemide (hearing loss of varying degrees may occur); anticoagulant activity of warfarin may be enhanced when taken concurrently; increased plasma lithium levels and toxicity are possible when taken concurrently |
| Pregnancy | C - Safety for use during pregnancy has not been established.
|
| Precautions | Prevents normal physiologic volume expansion that occurs in pregnancy and may reduce uterine blood flow; restrict use to women with volume-overload states (eg, renal or cardiac disease) |
Drug Category: Vasodilators
Decrease peripheral resistance by inducing vasodilation.
| Drug Name | Nitroprusside (Nitropress) |
| Description | Reduces peripheral resistance by acting directly on arteriolar and venous smooth muscle. Rapid-acting parenteral antihypertensive of short duration. Used occasionally for the treatment of eclampsia. Restricted to use in cases of severe hypertension not responsive to other drugs listed. Follow maternal cyanide and thiocyanate levels to prevent fetal toxicity. |
| Adult Dose | BP >170/110 mm Hg: 0.25 mcg/kg/min continuous infusion IV, titrate to BP with maximum dose of 5 mcg/kg/min; infusion rates >10 mcg/kg/min IV may lead to cyanide toxicity |
| Pediatric Dose | Administer as in adults |
| Contraindications | Documented hypersensitivity; subaortic stenosis, idiopathic hypertrophic and atrial fibrillation or flutter |
| Interactions | None reported |
| Pregnancy | C - Safety for use during pregnancy has not been established.
|
| Precautions | With prolonged (>4 h) use, concern exists regarding potential fetal cyanide toxicity; caution in increased intracranial pressure, hepatic failure, severe renal impairment, and hypothyroidism; in renal or hepatic insufficiency, nitroprusside levels may increase and can cause cyanide toxicity; sodium nitroprusside has the ability to lower blood pressure; use in patients with mean arterial pressures >70 mm Hg |
| Drug Name | Hydralazine (Apresoline) |
| Description | Intravenous form is useful when treating severe hypertension due to preeclampsia/eclampsia. Long record of safe use during pregnancy, but troublesome adverse effects occur. Decreases systemic resistance through direct vasodilation of arterioles. |
| Adult Dose | 10-20 mg/dose IV q4-6h prn initial; increase to 40 mg per dose prn BP >170/110 mm Hg: 0.1-0.2 mg/kg/dose IV q4-6h prn; not to exceed 20 mg or 1.7-3.5 mg/kg/d IV divided q4-6h |
| Pediatric Dose | Not established |
| Contraindications | Documented hypersensitivity; mitral valve rheumatic heart disease |
| Interactions | MAOIs and beta-blockers may increase hydralazine toxicity; indomethacin may decrease pharmacologic effects of hydralazine |
| Pregnancy | B - Usually safe but benefits must outweigh the risks.
|
| Precautions | Hydralazine has been implicated in myocardial infarction; caution in suspected coronary artery disease |
Drug Category: Anticonvulsants
Administered to prevent seizures in severe preeclampsia or eclampsia.
| Drug Name | Phenytoin (Dilantin) |
| Description | Less effective than magnesium at preventing eclamptic seizures but may be used if renal failure is present, magnesium fails, or serious magnesium-related toxicity occurs. May act in motor cortex where may inhibit spread of seizure activity. Activity of brain stem centers responsible for tonic phase of grand mal seizures also may be inhibited. |
| Adult Dose | 1000 mg IV over 1 h, followed by 500 mg PO 10 h later; not to exceed 1500 mg/24 h; rate of infusion not to exceed 50 mg/min to avoid hypotension and arrhythmias |
| Pediatric Dose | Not established |
| Contraindications | Documented hypersensitivity; heart block, myocardial damage, sinus bradycardia, Adams-Stokes syndrome; severe hepatitis; Addison disease |
| Interactions | Amiodarone, benzodiazepines, chloramphenicol, cimetidine, fluconazole, isoniazid, metronidazole, miconazole, phenylbutazone, succinimide, sulfonamides, omeprazole, phenacemide, disulfiram, ethanol (acute ingestion), trimethoprim, and valproic acid may increase phenytoin toxicity; phenytoin effects may decrease when taken concurrently with barbiturates, diazoxide, ethanol (chronic ingestion), rifampin, antacids, charcoal, carbamazepine, theophylline, and sucralfate; phenytoin may decrease effects of acetaminophen, corticosteroids, dicumarol, disopyramide, doxycycline, estrogens, haloperidol, amiodarone, carbamazepine, cardiac glycosides, quinidine, theophylline, methadone, metyrapone, mexiletine, oral contraceptives, and valproic acid |
| Pregnancy | C - Safety for use during pregnancy has not been established.
|
| Precautions | Perform blood counts and urinalyses when phenytoin therapy is begun and at monthly intervals for several mo to monitor for blood dyscrasias; discontinue use if a skin rash appears and do not resume use if rash is exfoliative, bullous, or purpuric; rapid phenytoin infusion may result in death from cardiac arrest, marked by QRS widening; caution in acute intermittent porphyria and diabetes (may elevate blood sugars); discontinue use if hepatic dysfunction occurs |
| Drug Name | Magnesium sulfate |
| Description | Women with eclampsia or severe preeclampsia should receive anticonvulsant therapy. Magnesium has been demonstrated to be superior to phenytoin for preventing and treating eclamptic seizures. |
| Adult Dose | 4-6 g IV load, followed by 2-3 g/h to maintain levels 4-8 mg/dL |
| Pediatric Dose | 20-100 mg/kg/dose IV q4-6h prn; in severe cases, may use doses as high as 200 mg/kg/dose IV |
| Contraindications | Documented hypersensitivity; heart block, myocardial damage; Addison disease; severe hepatitis |
| Interactions | Concurrent use of magnesium sulfate with nifedipine may cause hypotension and neuromuscular blockade; may increase neuromuscular blockade observed with aminoglycosides and potentiate neuromuscular blockade produced by tubocurarine, vecuronium, and succinylcholine; may increase CNS effects and toxicity of CNS depressants, betamethasone, and cardiotoxicity of ritodrine |
| Pregnancy | A - Safe in pregnancy
|
| Precautions | Levels of 8-12 mg/dL may cause loss of reflexes, diplopia, flushing, or slurring of speech; levels >12 mg/dL may cause muscular paralysis, ventilatory failure, and circulatory collapse; patients should have frequent neurological evaluations; loss of deep tendon reflex indicates that the magnesium level may be toxic; some clinicians follow serum magnesium levels q6h along with neurological examination; magnesium may alter cardiac conduction, leading to heart block in digitalized patients; in overdose, calcium gluconate 10-20 mL IV of 10% solution can be administered as antidote for clinically significant hypermagnesemia |
Further Inpatient Care
- When women have mild preeclampsia remote from term or labile blood pressures due to chronic hypertension and/or gestational hypertension, they often are admitted to hospital for bed rest and frequent fetal monitoring.
- The severity of any abnormalities on admission dictates the frequency of blood work.
- Daily examination should include a funduscopic examination for retinal spasm or edema, lung examination for signs of volume overload, cardiac examination for gallop rhythms, abdominal examination for hepatic tenderness, examination of extremities/sacrum for increasing edema, and neurologic examination for clonus.
- Treating hypertension secondary to preeclampsia with medications may reassure the clinician falsely but does not slow progression of the process; therefore, if treatment with antihypertensives is undertaken, clinicians must remain vigilant for all other symptoms, signs, and laboratory evidence of worsening preeclampsia.
- Other symptoms and signs of worsening preeclampsia must be sought routinely and delivery facilitated if the maternal or fetal condition worsens.
- Hypertension due to preeclampsia may worsen or even present in the postpartum period.
- After delivery, women with preeclampsia require ongoing close blood pressure monitoring. Blood pressure sustained greater than 160/110 mm Hg should be urgently treated with IV antihypertensives. Oral antihypertensive therapy should be undertaken for sustained pressures above 155/105 mm Hg.
- Blood pressure changes due to preeclampsia usually resolve within days to weeks after delivery but may persist for 3 months. Persistent hypertension beyond this point probably represents chronic hypertension.
Further Outpatient Care
- Women with preeclampsia require follow-up after hospital discharge to ensure normalization of blood pressure and any lab abnormalities noted. This follow-up may be undertaken via an internal medicine specialist (obstetric internist) and obstetrician or a family physician.
- Women with persistent hypertension due to preeclampsia require ongoing reassessment of their blood pressure. As vasospasm resolves, these women may be weaned off their antihypertensive therapy.
- Laboratory abnormalities related to preeclampsia (eg, proteinuria, thrombocytopenia, liver enzyme elevations) should be followed until the abnormalities return to the reference range. This is vital to ensure that no other underlying maternal medical disorder with potential long-term consequences is missed.
In/Out Patient Meds
- Available data suggest that all studied agents are excreted into human breast milk, but most are excreted to a negligible degree. All antihypertensive medications are believed to be compatible with breastfeeding, but using medications with a well-established record is reasonable.
- Atenolol, as well as the other beta-blocking agents nadolol and metoprolol, appear to be concentrated in breast milk. Labetalol and propranolol do not share this property and are preferred agents if a beta-blocker is indicated.
Transfer
Women with preeclampsia remote from term (ie, <34-36 weeks' gestation) should be promptly transferred to a facility with adequate resources to care for premature newborn infants. This is essential because worsening preeclampsia disease activity may require urgent delivery at any time.
Deterrence/Prevention
Multiple interventions to prevent preeclampsia have been investigated. Pharmacologic treatment and normalization of chronic hypertension does not reduce the risk of developing superimposed preeclampsia. Other therapies that have been tried include low-dose acetylsalicylic acid (ASA), supplemental calcium, salt restriction, supplemental magnesium, and fish oil therapy. While several large trials of ASA in high-risk populations showed minimal benefit in reducing the frequency of preeclampsia, a recent meta-analysis reported an approximate 15% reduction in preeclampsia among pregnant women taking low-dose ASA. This therapy appears very safe and might be considered in high-risk women. None of the other therapies have demonstrated any significant preventive benefit. One recent trial demonstrated some preventive benefit to supplemental antioxidants (vitamins C and E), but these results remain to be confirmed.
Complications
- Life-threatening complications in preeclampsia
- Seizures
- Cerebral hemorrhage
- Pulmonary edema - Due to pulmonary capillary leak, excess IV fluid administration, or myocardial dysfunction
- Acute renal failure - Due to renal vasospasm, ATN, or renal cortical necrosis
- Disseminated intravascular coagulopathy
- HELLP syndrome - Microangiopathic hemolysis, elevated liver enzymes, and thrombocytopenia (platelets [PLT] <100)
- Hepatic infarction/rupture and subcapsular hematoma - May lead to massive internal hemorrhage and shock
- Acute fatty liver of pregnancy: Although a distinct and rare disorder, acute fatty liver has some clinical features similar to, and often overlapping with, severe preeclampsia.
- TTP and HUS: While unrelated to preeclampsia, consider these important disorders in the setting of presumed severe HELLP syndrome.
Prognosis
- Women who develop preeclampsia during pregnancy have an increased risk of recurrent preeclampsia during subsequent pregnancies. The overall risk is about 18%. The risk is higher (50%) in women who develop severe early preeclampsia (ie, before 27 weeks' gestation).
- Transient hypertension of pregnancy, ie, the development of isolated hypertension in a woman in late pregnancy without other manifestations of preeclampsia, is associated strongly with later development of chronic hypertension.
Patient Education
Medical/Legal Pitfalls
Most internists do not have extensive exposure to diagnosing and treating medical disorders during pregnancy and therefore feel some discomfort doing so. Consult with an obstetric internist, maternal-fetal medicine specialist (perinatologist), and/or medical subspecialist. The experience of these experts allows them to assess quickly which treatments offer the best risk-benefit ratio. In most situations, the benefit of maximizing maternal well-being with the usual therapies outweighs potential adverse effects on the fetus.
Special Concerns
- Pregnancy
- Most patients enter pregnancy with the expectation that their pregnancy and delivery will involve nothing but happiness. When severe complications occur, patients often feel scared, angry, and helpless. The best approach is to discuss all issues with patients. Take all possible steps to help the patient and her family understand the complications and treatment. Begin the discussion by providing the diagnosis and reassure the pregnant woman that, in most cases, the complications are not due to her actions or failure to act. Follow with discussion of plans for evaluation and treatment, providing her an opportunity to ask questions. Empower the patient by involving her in the decision-making process.
- Patients ask very important questions. Physicians should feel comfortable being honest and telling patients and families when they do not have all of the answers. Physicians should let patients know that they will work to find the answers. This honesty and thoroughness solidifies the physician's reputation as a caring and competent doctor. Consultation with experienced clinicians helps the physician care for the patient and reassure her that all avenues of treatment are being explored.
- Many reference texts and articles are available regarding the treatment of medical disorders during pregnancy. Becoming educated about these topics helps physicians feel more comfortable treating and counseling patients.
| Media file 1:
Nonenhanced CT scan of a woman's brain following an eclamptic seizure, showing hypodense areas involving white matter of occipital lobes and high frontal/parietal lobes. Courtesy of Aashit K Shah, MD. |
 | View Full Size Image | |
Media type: CT
|
| Media file 2:
Axial T2-weighted MRIs of the brain of a woman with eclampsia, showing abnormal areas (hyperintense lesions) affecting pons, cerebral peduncles, and internal capsules. Courtesy of Aashit K Shah, MD. |
 | View Full Size Image | |
Media type: CT
|
| Media file 3:
Noncardiogenic pulmonary edema in a patient with preeclampsia. This is due to capillary leak that can be a primary component of preeclampsia. The radiograph demonstrates a diffuse increase in lung markings without cephalization or vascular redistribution seen in patients with pulmonary edema from systolic dysfunction. This patient had rapid clinical improvement after only 10 mg of intravenous furosemide. |
 | View Full Size Image | |
Media type: X-RAY
|
|